Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 164, Issue 3, 2011, Pages 389-395

  Bajuk Studen, Katica ^a   Šebeštjen, Miran ^a   Pfeifer, Marija ^a   Preželj, Janez ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; SPIRONOLACTONE; TESTOSTERONE; TRIACYLGLYCEROL; ANDROGEN; APOLIPOPROTEIN B; FOLLITROPIN; GLUCOSE; LUTEINIZING HORMONE; POTASSIUM; RENIN; ALDOSTERONE; ANTIANDROGEN; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DILATATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; ABSENCE OF SIDE EFFECTS; BODY MASS; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM CELL; HEMODYNAMICS; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WAIST CIRCUMFERENCE; BLOOD; CLINICAL TRIAL;

ADULT; ALDOSTERONE; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENEDIONE; DEHYDROEPIANDROSTERONE SULFATE; ENDOTHELIAL CELLS; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, LDL; POLYCYSTIC OVARY SYNDROME; POTASSIUM; RENIN; SPIRONOLACTONE; TESTOSTERONE; TRIGLYCERIDES; YOUNG ADULT;

EID: 79951965206     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0709     Document Type: Article

References (42)

1. Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1226. (doi:10.1056/NEJMra041536)
2. Meyer C, McGrath BP & Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardivascular disease. Journal of Clinical Endocrinology and Metabolism 2005 90 5711-5716. (doi:10.1210/jc.2005- 0011)
3. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB & Lobo RA. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. American Journal of Medicine 2006 119 e1-e6. (doi:10.1016/j.amjmed.2005.10.059)
4. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas I-A, Batakis N, Phenekos C & Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 2740-2746. (doi:10.1210/jc.2004-2363)
5. Shaw LJ, Bairey Merz N, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W & Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276-1284. (doi:10.1210/jc.2007-0425)
6. Christian RC, Dumesic DA, Behrenbeck T, Oberg AI, Sheedy PF II & Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 2562-2568. (doi:10.1210/jc.2003-030334)
7. Wierzbicki AS, Chowienczyk PJ, Cockroft JR, Brett SE, Watts GF, Jenkins BS & Ritter JM. Cardiovascular risk factors and endothelial dysfunction. Clinical Science 2004 107 609-615. (doi:10.1042/CS20040078)
8. Deanfield JE, Halcoy JP & Rabelink TJ. Endothelial function and dysfunction. Circulation 2007 115 1285-1295. (doi:10.1161/CIRCULATIONAHA.106. 652859)
9. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G & Shepard MK. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 103 1410-1415. (Pubitemid 32220633)
10. Orio F Jr, Palomba S, Cascella T, DeSimone B, DiBiase S & Russo T. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 4588-4593. (doi:10.1210/jc.2003-031867)
11. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J & Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology 2005 152 749-756. (doi:10.1530/eje.1.01910)
12. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A & Michalis LK. Predictors of endothelial dysfunction in young women with PCOS. Journal of Clinical Endocrinology and Metabolism 2005 90 5088-5095. (doi:10.1210/jc.2005- 0151)
13. Cascella T, Palomba S, Tauchmanovà L, Manguso F, DiBiase S, Labella D, Giallauria F, Vigorito C, Colao A, Lombardi G & Orio F. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 4395-4400. (doi:10.1210/jc.2006-0399)
14. Brown J, Farquhar C, Lee O, Toomath R & Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews 2009 15 CD000194. (doi:10.1002/14651858. CD000194.pub2)
15. Sowers JR, Whaley-Connell A & Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of Internal Medicine 2009 150 776-783.
16. Zawadski JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam. Boston, MA: Blackwell Scientific, 1992.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
18. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S & Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility 2004 82 893-902. (doi:10.1016/j.fertnstert.2004.02.127)
19. Shapiro G & Evron S. A novel use of spironolactone: treatment of hirsutism. Journal of Clinical Endocrinology and Metabolism 1980 51 429-432. (doi:10.1210/jcem-51-3-429)
20. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK & Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 1111-1115. (doi:10.1016/0140-6736(92)93147-F)
21. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I & Pfeifer M. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. European Journal of Endocrinology 2008 159 399-406. (doi:10.1530/EJE-08-0507)
22. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR & Herrington DM. Predictive value of brachial flow-mediated dilatation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009 120 502-509. (doi:10.1161/CIRCULATIONAHA.109.864801)
23. Charakida M, Masi S, Luscher T, Kastelein JJP & Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. European Heart Journal 2010 31 2854-2861. (doi:10.1093/eurheartj/ehq340)
24. Romualdi D, Costantini B, Selvaggi L, Giuliani M, Cristello F, Macri F, Bompiani A, Lanzone A & Guido M. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new perspective. Human Reproduction 2008 23 2127-2133. (doi:10.1093/humrep/den230)
25. Fujimoto R, Morimoto I, Morita E, Sugimoto H, Ito Y & Eto S. Androgen receptors, 5a-reductase activity and androgendependent proliferation of vascular smooth muscle cells. Journal of Steroid Biochemistry and Molecular Biology 1994 50 169-174. (doi:10.1016/0960-0760(94)90025-6)
26. Hutchison SJ, Sudhir K, Chou TM, Sievers RE, Zhu BQ, Sun YP, Deedwania PC, Glantz SA, Parmley WW & Chatterjee K. Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. Journal of the American College of Cardiology 1997 29 800-807. (doi:10.1016/S0735-1097(96)00570-0)
27. Spritzer PM, Lisboa KO, Mattiello S & Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clinical Endocrinology 2000 52 587-594. (doi:10.1046/j.1365-2265.2000.00982.x)
28. Menard RH, Stripp B & Gillette JR. Spironolactone and testicular cytochrome p-450: decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology 1974 94 1628-1636. (doi:10.1210/endo-94-6-1628)
29. Chiau-Cheng S, Suzuki K, Sadee W & Harding BW. Effect of spironolactone, canrenone and K-canreonate on cytochrome p-450 and 11β- and 18 hydroxilation in bovine and human adrenal cortical mitochondria. Endocrinology 1976 99 1097-1102. (doi:10.1210/endo-99-4-1097)
30. Diamanti-Kandarakis E, Economou FN, Livadas E, Tantalaki E, Piperi C, Papavassiliou AG & Panidis D. Hypereninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney & Blood Pressure Research 2009 32 24-31. (doi:10.1159/000201791)
31. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine 1999 341 709-717. (doi:10.1056/NEJM199909023411001)
32. Farquharson CA & Struthers AD. Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and supresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000 101 594-597. (Pubitemid 30094728)
33. Davies JI, Band M, Morris A & Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004 47 1687-1694. (doi:10.1007/s00125-004-1510-8)
34. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga- Thie GM, Fauser BC, Westerveld EH & Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. Journal of Clinical Endocrinology and Metabolism 2008 93 470-476. (doi:10.1210/jc.2007-1756)
35. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoglu G, Yesilkaya E & Hasanoglu A. Serum leptin, oxidized low density lipoprotein, and plasma asymmetric dimethylarginine levels and their relationship with dyslipidemia in adolescent girls with polycystic ovary syndrome. Clinical Endocrinology 2007 67 129-134. (doi:10.1111/j.1365-2265.2007.02849.x)
36. Legro RS, Kunselman AR & Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 2001 111 607-613. (doi:10.1016/S0002-9343(01)00948-2)
37. Adams MR, Kinlay S, Blake GJ, Orford JL, Ganz P & Selwyn A. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndromes. Annual Review of Medicine 2000 51 149-167. (doi:10.1146/annurev.med.51.1.149)
38. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G & Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 2699-2705. (doi:10.1210/jc.83.8.2699)
39. Lakhani K, Seifalian AM&Hardiman P. Impaired carotid viscoelastic properties in women with polycystic ovaries. Circulation 2002 106 81-85. (doi:10.1161/01.CIR.0000020681.19400.8A)
40. Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H & Connell JMC. Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 742-746. (doi:10.1210/jc.87.2. 742)
41. Azziz R. Controversy in clinical endocrinology - diagnosis of polycystic ovary syndrome: the Rotterdam Criteria are premature. Journal of Clinical Endocrinology and Metabolism 2006 91 781-785. (doi:10.1210/jc.2005-2153)
42. Herrera MD, Mingorance C, Rodriguez-Rodriguez R & Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Ageing Research Reviews 2010 9 142-152. (doi:10.1016/j.arr.2009.07.002)